(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 14 April 2005 (14.04.2005)

PCT

(10) International Publication Number WO 2005/033056 A3

C07D 333/38, (51) International Patent Classification⁷: 307/54, 261/18, 211/14, A61K 31/495, 31/381, 31/341, A61P 15/02, 19/10, 35/00

(21) International Application Number:

PCT/US2004/032918

(22) International Filing Date: 4 October 2004 (04.10.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

8 October 2003 (08.10.2003) 60/509,678 US 60/514,692 27 October 2003 (27.10.2003) US

(71) Applicant (for all designated States except US): **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): EADDY, III, John, Fred [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). HEYER, Dennis [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). KATAMREDDY, Subba, Reddy [IN/US]; Glaxo-SmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). MARTIN, Michael, Tolar [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). MCCLURE, Michael, Scott [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). RANDHAWA, Amarjit, Sab [CA/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). SAMANO, Vicente [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

RAY, John, Albert [US/US]; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agents: LEVY, David, J et al.; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


with international search report

before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 23 June 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRIPHENYLETHYLENE COMPOUNDS AS SELECTIVE ESTROGEN RECEPTOR MODULATORS



(57) Abstract: The present invention relates to novel compounds of Formula (I) with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation. R1 is -C(O)-alkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-cycloalkyl, -C(O)-(CH₂)_n-NR⁴R⁵, -C(O)-O-alkyl, $C(O)-(CH_2)_n-O-alkyl$, $-C(O)-(CH_2)_n-haloalkyl$, $-C(O)-(CH_2)_n-haloalkyl$, $-C(O)-(CH_2)_n-haloalkyl$ cyl, or -PO 3 H 2; R4 and R5 each independently are selected from H and alkyl; and n is 1 to 6.